oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 42 )

2018 ( 233 )

2017 ( 217 )

2016 ( 299 )

Custom range...

Search Results: 1 - 10 of 119729 matches for " T. Saito "
All listed articles are free for downloading (OA Articles)
Page 1 /119729
Display every page Item
The additivity of the pseudo-additive conditional entropy for a proper Tsallis' entropic index
T. Wada,T. Saito
Physics , 2001, DOI: 10.1016/S0378-4371(01)00659-8
Abstract: For Tsallis' entropic analysis to the time evolutions of standard logistic map at the Feigenbaum critical point, it is known that there exists a unique value $q^*$ of the entropic index such that the asymptotic rate $K_q \equiv \lim_{t \to \infty} \{S_q(t)-S_q(0)\} / t$ of increase in $S_q(t)$ remains finite whereas $K_q$ vanishes (diverges) for $q > q^* (q < q^*)$. We show that in spite of the associated whole time evolution cannot be factorized into a product of independent sub-interval time evolutions, the pseudo-additive conditional entropy $S_q(t|0) \equiv \{S_q(t)-S_q(0)\}/ \{1+(1-q)S_q(0)\}$ becomes additive when $q=q^*$. The connection between $K_{q^*}$ and the rate $K'_{q^*} \equiv S_{q^*}(t | 0) / t$ of increase in the conditional entropy is discussed.
Ionospheric height variations observed by ionosondes along magnetic meridian and plasma bubble onsets
S. Saito ,T. Maruyama
Annales Geophysicae (ANGEO) , 2006,
Abstract: Since October 2004, a Frequency Modulated–Continuous Wave (FM–CW) ionosonde chain along the magnetic meridian has been operating in Southeast Asia, in Kototabang (0.2° S, 100.3° E), Indonesia, Chumphon (10.7° N, 99.4° E), Thailand, and Chiang Mai (18.8° N, 98.9° E), Thailand. Variations in the virtual height of the bottomside of the F-region (h'F) at 2.5 MHz were analyzed, in order to study the day-to-day variability of plasma bubble occurrence for the periods of October 2004 and March–April 2005. When plasma bubbles were generated, h'F was enhanced at the three stations. However, even when h'F at the equatorial station, Chumphon, was largely enhanced, plasma bubbles were not generated when a noticeable north-south asymmetry of h'F existed. This asymmetry could be attributed to the transequatorial thermospheric wind. Our results show that the strong transequatorial thermospheric wind can suppress the plasma bubble generation and is one of the important factors which controls the day-to-day variability of plasma bubble occurrences.
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
Takami T, Saito Y
Drug Design, Development and Therapy , 2013, DOI: http://dx.doi.org/10.2147/DDDT.S42338
Abstract: zelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial Original Research (510) Total Article Views Authors: Takami T, Saito Y Published Date March 2013 Volume 2013:7 Pages 175 - 183 DOI: http://dx.doi.org/10.2147/DDDT.S42338 Received: 04 January 2013 Accepted: 25 February 2013 Published: 22 March 2013 Takeshi Takami,1 Yoshihiko Saito2 1Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, Japan Purpose: To compare the long-term effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP), left ventricular (LV) mass index (LVMI), LV diastolic function (e′ velocity, E/e′ ratio, E/A ratio) and arterial stiffness (brachial-ankle pulse wave velocity [baPWV] and augmentation index normalized for a heart rate of 75 bpm [AIx]). Patients and methods: Patients with systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg received olmesartan monotherapy (20 mg/day) for 12 weeks. They were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg/day; n = 26) or amlodipine (5 mg/day; n = 26) for a further 2 years. CBP, LVMI, e′ velocity, E/e′ratio, E/A ratio, baPWV, and AIx were measured at baseline, 6 months, and 2 years. Results: Baseline characteristics of both groups were similar. The decrease in brachial BP over 2 years was similar in both groups. CBP, LVMI, E/e′ ratio, baPWV, and AIx decreased significantly, and the E/A ratio and e′ velocity increased significantly in both groups. The decreases in CBP (P < 0.001), AIx (P < 0.001), baPWV (P < 0.001), LVMI (P < 0.001), and E/e′ (P = 0.002) as well as the increase in E/A ratio (P = 0.03) over 2 years were significantly greater in the olmesartan/azelnidipine group than in the olmesartan/amlodipine group. Multivariate linear regression analyses showed that the changes in baPWV (β = 0.41, P < 0.001) and CBP (β = 0.47, P = 0.01) were independently associated with the change in LVMI, the change in baPWV (β = 0.25, P < 0.001) was independently associated with the change in E/e′ ratio, and the changes in baPWV (β = 0.21, P = 0.001) and AIx (β = 0.25, P = 0.03) were independently associated with the change in E/A ratio. Conclusion: Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine. Improvements in LV diastolic function were associated with improvements in arterial stiffness.
Effects of smoking cessation on central blood pressure and arterial stiffness
Takami T, Saito Y
Vascular Health and Risk Management , 2011, DOI: http://dx.doi.org/10.2147/VHRM.S25798
Abstract: ts of smoking cessation on central blood pressure and arterial stiffness Original Research (4097) Total Article Views Authors: Takami T, Saito Y Published Date October 2011 Volume 2011:7 Pages 633 - 638 DOI: http://dx.doi.org/10.2147/VHRM.S25798 Takeshi Takami1,Yoshihiko Saito2 1Department of Internal Medicine, Clinic Jingumae, Kashihara, Nara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan Purpose: Smoking affects arterial stiffness, thus causing an elevation in central blood pressure (CBP). The present study was designed to examine whether smoking cessation treatment improved CBP and arterial stiffness. Patients and methods: We conducted an observational study of 70 patients receiving smoking cessation treatment. Before and 60 weeks after the start of a 12-week varenicline treatment, we measured brachial blood pressure, CBP, brachial-ankle pulse wave velocity (baPWV), normalized radial augmentation index (rAIx@75), left ventricular weight, and left ventricular diastolic function of each patient. The data were compared between the patients who succeeded in quitting smoking (smoking cessation group; n = 37) and those who failed to quit smoking (smoking group; n = 33). Results: Baseline characteristics were similar in both groups. Brachial blood pressure remained unchanged in both groups. CBP, baPWV, and rAIx@75 decreased significantly in the smoking cessation group, while these parameters showed no significant change in the smoking group. Thus, CBP, baPWV, and rAIx@75 showed greater decrease in the smoking cessation group than in the smoking group (CBP, 7.1 ± 1.4 mmHg vs 1.2 ± 2.7 mmHg; P < 0.01; baPWV, 204 ± 64 cm/s vs 43 ± 72 cm/s; P < 0.01; rAIx@75, 6.4 ± 2.8% vs 1.0 ± 3.9%; P < 0.01). Left ventricular weight and left ventricular diastolic function remained unchanged in both groups. Conclusion: Patients in the smoking cessation group showed significant improvement in CBP, baPWV, and rAIx@75. These results indicate that smoking cessation can improve arterial stiffness and CBP.
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
Takami T, Saito Y
Vascular Health and Risk Management , 2011, DOI: http://dx.doi.org/10.2147/VHRM.S21991
Abstract: ts of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study Original Research (19259) Total Article Views Authors: Takami T, Saito Y Published Date June 2011 Volume 2011:7 Pages 383 - 390 DOI: http://dx.doi.org/10.2147/VHRM.S21991 Takeshi Takami1, Yoshihiko Saito2 1Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, Japan Purpose: The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. Patient and methods: Patients with brachial systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg received olmesartan monotherapy (20 mg daily) for 12 weeks. The patients were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg daily) or amlodipine (5 mg daily) (25 patients/group) for a further 24 weeks. CBP and LVMI were measured at baseline and at the end of the study. Results: Baseline characteristics were similar in both groups. The decrease in brachial BP was similar in both groups. CBP and LVMI decreased significantly in both groups (both, P < 0.001). However, the decreases in CBP and LVMI were significantly greater with olmesartan/azelnidipine than with olmesartan/amlodipine (CBP, P < 0.001; LVMI, P = 0.002). Conclusions: These findings indicate that olmesartan/azelnidipine had greater effects on CBP and LVMI than did olmesartan/amlodipine, even though the reduction in brachial BP was similar in both groups. These differential effects on CBP and LVMI may have important implications for cardiovascular risk reduction.
Effects of smoking cessation on central blood pressure and arterial stiffness
Takami T,Saito Y
Vascular Health and Risk Management , 2011,
Abstract: Takeshi Takami1,Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Nara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, JapanPurpose: Smoking affects arterial stiffness, thus causing an elevation in central blood pressure (CBP). The present study was designed to examine whether smoking cessation treatment improved CBP and arterial stiffness.Patients and methods: We conducted an observational study of 70 patients receiving smoking cessation treatment. Before and 60 weeks after the start of a 12-week varenicline treatment, we measured brachial blood pressure, CBP, brachial-ankle pulse wave velocity (baPWV), normalized radial augmentation index (rAIx@75), left ventricular weight, and left ventricular diastolic function of each patient. The data were compared between the patients who succeeded in quitting smoking (smoking cessation group; n = 37) and those who failed to quit smoking (smoking group; n = 33).Results: Baseline characteristics were similar in both groups. Brachial blood pressure remained unchanged in both groups. CBP, baPWV, and rAIx@75 decreased significantly in the smoking cessation group, while these parameters showed no significant change in the smoking group. Thus, CBP, baPWV, and rAIx@75 showed greater decrease in the smoking cessation group than in the smoking group (CBP, 7.1 ± 1.4 mmHg vs 1.2 ± 2.7 mmHg; P < 0.01; baPWV, 204 ± 64 cm/s vs 43 ± 72 cm/s; P < 0.01; rAIx@75, 6.4 ± 2.8% vs 1.0 ± 3.9%; P < 0.01). Left ventricular weight and left ventricular diastolic function remained unchanged in both groups.Conclusion: Patients in the smoking cessation group showed significant improvement in CBP, baPWV, and rAIx@75. These results indicate that smoking cessation can improve arterial stiffness and CBP.Keywords: central blood pressure, augmentation index, brachial-ankle pulse wave velocity, smoking cessation, varenicline
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
Takami T,Saito Y
Vascular Health and Risk Management , 2011,
Abstract: Takeshi Takami1, Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, JapanPurpose: The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients.Patient and methods: Patients with brachial systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg received olmesartan monotherapy (20 mg daily) for 12 weeks. The patients were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg daily) or amlodipine (5 mg daily) (25 patients/group) for a further 24 weeks. CBP and LVMI were measured at baseline and at the end of the study.Results: Baseline characteristics were similar in both groups. The decrease in brachial BP was similar in both groups. CBP and LVMI decreased significantly in both groups (both, P < 0.001). However, the decreases in CBP and LVMI were significantly greater with olmesartan/azelnidipine than with olmesartan/amlodipine (CBP, P < 0.001; LVMI, P = 0.002).Conclusions: These findings indicate that olmesartan/azelnidipine had greater effects on CBP and LVMI than did olmesartan/amlodipine, even though the reduction in brachial BP was similar in both groups. These differential effects on CBP and LVMI may have important implications for cardiovascular risk reduction.Keywords: central blood pressure, left ventricular mass index, augmentation index, brachial-ankle pulse wave velocity, olmesartan/azelnidipine
A note on infinite divisibility of zeta distributions
S. Saito,T. Tanaka
Applied Mathematical Sciences , 2012,
Abstract:
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
Takami T,Saito Y
Drug Design, Development and Therapy , 2013,
Abstract: CorrigendumTakami T, Saito Y. Drug Design, Development and Therapy. 2013;7:175–183. On page 177, line 26, heading "Measurement of LVMI and LF diastolic function" should have been "Measurement of LVMI and LV diastolic function". Line 32, "Devereux et al18" should read "Devereux et al19". Line 40, "(E/e’ ratio) were measured as previously described.19" should read "(E/e’ ratio) were measured as previously described.20". On page 181, line 15, "baPWV with LVMI.20" should read "baPWV with LVMI.21". Line 23, "baPWV and LVMI, E/A ratio.20" should read "baPWV and LVMI, E/A ratio.21,22". Line 28 "diastolic dysfunction.21" should read "diastolic dysfunction.23". Line 38 "is high.22" should read "is high.24". Line 39, "in clinical treatment.23" should read "in clinical treatment.25". Line 57, "A recent cohort study24" should read "A recent cohort study21".On page 182, line 1, "diastolic heart failure.25" should read "diastolic heart failure.26". Line 3, "untreated hypertensive patients.26" should read "untreated hypertensive patients.27". Line 6, "linear regression analysis.27" should read "linear regression analysis.21".On page 183, the references 18 to 27 should be updated as shown below:18. Takami T. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic. Hypertens Res. 2009;32:1086–1090.19. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation. 2001;104:1248–1254.20. Ito H, Ishii K, Kihara H, et al. Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. Hypertens Res. 2012;35:93–99.21. Xu L, Jiang CQ, Lam TH, et al. Arterial stiffness and left-ventricular diastolic dysfunction: Guangzhou Biobank Cohort Study-CVD. J Hum Hypertens. 2011;25:152–158.22. Kim MN, Park SM, Shim WJ, et al. The relationship between aortic stiffness and left ventricular dyssynchrony in hypertensive patients with preserved left ventricular systolic function. Clin Exp Hypertens. 2012;34:410–416.23. Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39:2005–2011.24. Ommen SR, Nishimura RA, Appleton CP, et al. Cl
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
Takami T,Saito Y
Drug Design, Development and Therapy , 2013,
Abstract: Takeshi Takami,1 Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, JapanPurpose: To compare the long-term effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP), left ventricular (LV) mass index (LVMI), LV diastolic function (e′ velocity, E/e′ ratio, E/A ratio) and arterial stiffness (brachial-ankle pulse wave velocity [baPWV] and augmentation index normalized for a heart rate of 75 bpm [AIx]).Patients and methods: Patients with systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg received olmesartan monotherapy (20 mg/day) for 12 weeks. They were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg/day; n = 26) or amlodipine (5 mg/day; n = 26) for a further 2 years. CBP, LVMI, e′ velocity, E/e′ratio, E/A ratio, baPWV, and AIx were measured at baseline, 6 months, and 2 years.Results: Baseline characteristics of both groups were similar. The decrease in brachial BP over 2 years was similar in both groups. CBP, LVMI, E/e′ ratio, baPWV, and AIx decreased significantly, and the E/A ratio and e′ velocity increased significantly in both groups. The decreases in CBP (P < 0.001), AIx (P < 0.001), baPWV (P < 0.001), LVMI (P < 0.001), and E/e′ (P = 0.002) as well as the increase in E/A ratio (P = 0.03) over 2 years were significantly greater in the olmesartan/azelnidipine group than in the olmesartan/amlodipine group. Multivariate linear regression analyses showed that the changes in baPWV (β = 0.41, P < 0.001) and CBP (β = 0.47, P = 0.01) were independently associated with the change in LVMI, the change in baPWV (β = 0.25, P < 0.001) was independently associated with the change in E/e′ ratio, and the changes in baPWV (β = 0.21, P = 0.001) and AIx (β = 0.25, P = 0.03) were independently associated with the change in E/A ratio.Conclusion: Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine. Improvements in LV diastolic function were associated with improvements in arterial stiffness.Keywords: central blood pressure, arterial stiffness, left ventricular mass index, left ventricular diastolic function, olmesartan/azelnidipine
Page 1 /119729
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.